News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Micrologix Biotech Inc. (MGIXF) Conference Call Notification - MBI 594AN Phase IIb Results


10/19/2005 5:10:46 PM

VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ -- Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) has scheduled a conference call and web cast for Monday, November 17, 2003 at 9:00 a.m. ET (6:00 a.m. PT) to discuss results from the Phase IIb clinical trial of MBI 594AN. It is anticipated that the results of the trial will be released prior to the conference call.

About the Conference Call

To participate in the conference call, please dial 416-405-9328 or 1-800- 387-6216. The call will be available for replay until December 1, 2003 by calling 1-800-408-3053 or 416-695-5800 and entering the pass code 1498266. The live or archived web cast can be accessed through the company's website at http://www.mbiotech.com/.

About Micrologix

Micrologix Biotech Inc. is engaged in the research, development, and commercialization of drugs that advance therapy, improve health, and enrich lives. The Company's focus is toward anti-infective drug development with three product candidates in human clinical studies, multiple product opportunities in preclinical development, and several early-stage technologies in various stages of research and evaluation.

Investor & Media Relations Contacts: Jonathan Burke Micrologix Biotech Inc. Telephone: 604.221.9666 Extension 241 Toll-Free: 1.800.665.1968 E-mail: jburke@mbiotech.com Shayne Payne/Dian Griesel, Ph.D The Investor Relations Group Telephone: 212-825-3210 Email: theproteam@aol.com

Micrologix Biotech Inc.

CONTACT: Investor & Media Relations Contacts: Jonathan Burke, MicrologixBiotech Inc., Telephone: 604-221-9666 Extension 241, Toll-Free:1-800-665-1968, E-mail: jburke@mbiotech.com; Shayne Payne/Dian Griesel,Ph.D, The Investor Relations Group, Telephone: 212-825-3210, Email:theproteam@aol.com;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES